Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 8/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | APP | P05067 | 2/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6539361 | 0.99 | KMT2A (0.43) | KMT2AMEN1KDM4EHPGDNPSR1 | |
| SCHEMBL6236506 | 0.89 | PPARD (0.43) | KMT2AMEN1KDM4EHPGDNPSR1 | |
| SCHEMBL6539657 | 0.88 | PPARD (0.43) | KMT2AMEN1KDM4EHPGDNPSR1 | |
| Hydrochloric Acid SCHEMBL6538837 | 0.87 | PPARD (0.42) | KMT2AMEN1KDM4EHPGDNPSR1 | |
| SCHEMBL6207503 | 0.83 | PPARD (0.40) | KMT2AMEN1KDM4EHPGDNPSR1 | |
| SCHEMBL6206961 | 0.83 | MTNR1A (0.44) | KMT2AMEN1KDM4EHPGDNPSR1 | |
| SCHEMBL6258696 | 0.83 | PPARD (0.40) | KMT2AMEN1KDM4EHPGDPPARD | |
| SCHEMBL6207074 | 0.82 | ALDH1A1 (0.41) | KMT2AMEN1KDM4EHPGDNPSR1 | |
| SCHEMBL6539712 | 0.81 | NPSR1 (0.50) | KMT2AMEN1NPSR1PPARDALDH1A1 | |
| SCHEMBL6538831 | 0.81 | ESR2 (0.47) | KMT2AMEN1KDM4EHPGDNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1583749-A1 | OXAZOLE DERIVATIVES AS INHIBITORS OF CYCLOOXYGENASE | Astellas Pharma Inc. (JP) | 2005-10-12 | — | — | EP | disclosed |
| US-20040157891-A1 | Inhibitor of cox | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-08-12 | — | — | US | disclosed |
| WO-2004065374-A1 | OXAZOLE DERIVATIVES AS INHIBITORS OF CYCLOOXYGENASE | ASTELLAS PHARMA INC. (JP) | 2004-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157891-A1 | Inhibitor of cox | PTGS1, PTGS2, PTGES2 | KMT2A 3081/4885MEN1 4420/4885KDM4E 1912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.